Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study (Q42621663)

3 November 2017

title

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study (English)

1 reference

3 November 2017

main subject

metastatic breast cancer

1 reference

Kostandinos Sideras

12

0 references

Peter Barrett-Lee

object named as

Peter J Barrett-Lee

10

0 references

Edith A. Perez

18

object named as

Edith A Perez

1 reference

3 November 2017

16

Ute Hoch

1 reference

3 November 2017

Ahmad Awada

1

1 reference

3 November 2017

Agustin A Garcia

2

1 reference

3 November 2017

Stephen Chan

3

1 reference

3 November 2017

Guy H M Jerusalem

4

1 reference

3 November 2017

Robert E Coleman

5

1 reference

3 November 2017

Manon T Huizing

6

1 reference

3 November 2017

Aminder Mehdi

7

1 reference

3 November 2017

Sue M O'Reilly

8

1 reference

3 November 2017

John T Hamm

9

1 reference

3 November 2017

Veronique Cocquyt

11

1 reference

3 November 2017

David E Young

13

1 reference

3 November 2017

Carol Zhao

14

1 reference

3 November 2017

Yen Lin Chia

15

1 reference

3 November 2017

Alison L Hannah

17

1 reference

3 November 2017

NKTR-102 Study Group

19

1 reference

3 November 2017

publication date

4 October 2013

1 reference

Lancet Oncology Commission

3 November 2017

published in

1 reference

3 November 2017

volume

14

1 reference

3 November 2017

issue

12

1 reference

3 November 2017

page(s)

1216-1225

1 reference

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine

3 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970429-7

7 January 2021

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970429-7

7 January 2021

A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970429-7

7 January 2021

Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970429-7

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970429-7

7 January 2021

Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients With Metastatic Breast Cancer Previously Untreated With Taxanes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970429-7

7 January 2021

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970429-7

7 January 2021

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970429-7

7 January 2021

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970429-7

7 January 2021

Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970429-7

7 January 2021

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970429-7

7 January 2021

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970429-7

7 January 2021

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970429-7

7 January 2021

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970429-7

7 January 2021

Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970429-7

7 January 2021

Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970429-7

7 January 2021

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970429-7

7 January 2021

10.1016/S1470-2045(13)70429-7

Identifiers

DOI

1 reference

3 November 2017

1 reference